Cytokine Release Syndrome
CAR-T will ‘play a very important role’ in multiple myeloma treatment landscape
The FDA approval of the first ever chimeric antigen receptor T-cell therapy for multiple myeloma in 2021 laid the groundwork for others to follow.
COVID-19-driven shortage of tocilizumab may impact delivery of CAR T-cell therapy
The FDA has included tocilizumab among its list of drugs currently in shortage.
Lenzilumab before CAR-T induces high response rates without severe toxicities
A combination of lenzilumab and axicabtagene ciloleucel induced an 83% overall response rate among patients with advanced diffuse large B-cell lymphoma, according to topline data released by the agent’s manufacturer.
Anakinra shows promise as steroid-sparing agent for CAR T-cell therapy-related toxicities
Steroids are commonly used to mitigate severe treatment-related adverse events associated with chimeric antigen receptor T-cell therapy.
Guidelines provide consensus on management of CAR T-cell therapy-related toxicities
The Society for Immunotherapy of Cancer published clinical practice guidelines on the management of toxicities related to the use of immune effector cell therapies, including chimeric antigen receptor T cells.
VIDEO: CAR-T techniques could be applied to COVID-19 management
Neetu Gupta, PhD, associate professor at Cleveland Clinic Foundation, discussed data comparing cytokine release syndrome in CAR T-therapy to COVID-19 at the ASH Annual Meeting and Exposition.
CAR-T-associated cardiac toxicity ‘limited and reversible’ in younger patients with ALL
Cardiovascular toxicity associated with chimeric antigen receptor T-cell therapy is both limited and reversible among high-risk children and young adults with acute lymphoblastic leukemia, according to results of a phase 1 clinical trial.
CAR-T plus pembrolizumab shows ‘superior’ safety, promising responses in advanced lymphoma
No patients who received pembrolizumab with a CD19/CD22-directed chimeric antigen receptor T-cell therapy experienced high-grade cytokine release syndrome, according to phase 1 study findings presented during ESMO Virtual Congress 2020.
Limiting severe toxicity, mortality after CAR T-cell therapy
In this installment of In Practice, Marco L. Davila, MD, PhD, and Rawan G. Faramand, MD, of H. Lee Moffitt Cancer Center and Research Institute in Tampa, discuss the importance of developing a patient-specific management strategy to limit severe toxicities and mortality after chimeric antigen receptor T-cell therapy.
Frantic search for COVID-19 cure gives rise to ‘Wild West’ of clinical trials
Keeping pace with the worldwide “deluge” of clinical trial developments pertaining to COVID-19 can be a full-time job, according to a presenter at the 2020 Association of Women in Rheumatology National Conference.